Department of Surgery, Murtha Cancer Center Research Program (MCCRP), F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences (USUHS), Bethesda, MD, USA.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Ann Surg Oncol. 2024 Nov;31(12):8196-8205. doi: 10.1245/s10434-024-15941-2. Epub 2024 Jul 31.
We aimed to compare Asian or Pacific Islander, Black, Hispanic, and non-Hispanic White patients in treatment for papillary thyroid cancer (PTC) in the equal access Military Health System to better understand racial-ethnic cancer health disparities observed in the United States.
We used the MilCanEpi database to identify a cohort of men and women aged 18 or older who were diagnosed with PTC between 1998 and 2014. Low- or high-risk status was assigned using tumor size and lymph node involvement. Treatment with surgery (e.g., thyroidectomy) overall and treatment by risk status [active surveillance (low-risk) or adjuvant radioactive iodine (RAI) (high-risk)] was compared between racial-ethnic groups using multivariable logistic regression and expressed as adjusted odds ratios (AOR) with 95% confidence intervals (CIs).
The study included 598 Asian, 553 Black, 340 Hispanic, and 2958 non-Hispanic White patients with PTC. Asian (AOR = 1.21, 95% CI 0.98, 1.49), Black (AOR = 1.07, 95% CI 0.87, 1.32), and Hispanic (AOR = 0.92, 95% CI 0.71, 1.19) patients were as likely as White patients to receive surgery. By risk status, there were no significant racial-ethnic differences in receipt of active surveillance or thyroidectomy for low-risk PTC or in thyroidectomy or total thyroidectomy with adjuvant RAI for high-risk PTC.
In the Military Health System, where patients have equal access to care, there were no overall racial-ethnic differences in surgical treatment for PTC. As American Thyroid Association guidelines evolve to include more conservative treatment, further research is warranted to understand potential disparities in active surveillance and surgical management in U.S. healthcare settings.
我们旨在比较在享有平等医疗机会的军事卫生系统中接受甲状腺乳头状癌(PTC)治疗的亚洲或太平洋岛民、非裔、西班牙裔和非西班牙裔白人患者,以更好地理解在美国观察到的种族-族裔癌症健康差异。
我们使用 MilCanEpi 数据库来确定 1998 年至 2014 年间被诊断患有 PTC 的 18 岁及以上的男性和女性队列。使用肿瘤大小和淋巴结受累情况来确定低危或高危状态。使用多变量逻辑回归比较种族-族裔群体之间的整体手术治疗(例如甲状腺切除术)和根据风险状况的治疗[主动监测(低危)或辅助放射性碘(RAI)(高危)],并表示为调整后的优势比(AOR)和 95%置信区间(CI)。
该研究纳入了 598 名患有 PTC 的亚洲人、553 名黑人、340 名西班牙裔和 2958 名非西班牙裔白人患者。亚洲人(AOR=1.21,95%CI 0.98,1.49)、黑人(AOR=1.07,95%CI 0.87,1.32)和西班牙裔(AOR=0.92,95%CI 0.71,1.19)患者与白人患者一样有可能接受手术。按风险状况,在接受低危 PTC 的主动监测或甲状腺切除术,或高危 PTC 的甲状腺切除术或甲状腺全切除术联合辅助 RAI 方面,没有明显的种族-族裔差异。
在享有平等医疗机会的军事卫生系统中,对 PTC 的手术治疗没有总体的种族-族裔差异。随着美国甲状腺协会指南的不断发展,纳入了更保守的治疗方法,因此有必要进一步研究,以了解美国医疗保健环境中主动监测和手术管理方面的潜在差异。